CB
VKTX icon

CNB Bank’s Viking Therapeutics VKTX Stock Holding History

CNB Bank’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Sell
276
-2,821
-91% -$91.1K ﹤0.01% 419
2026
Q1 		$101K Sell
3,097
-963
-24% -$31K 0.04% 204
2025
Q4 		$143K Sell
4,060
-1,696
-29% -$60.1K 0.06% 179
2025
Q3 		$151K Buy
5,756
+279
+5% +$8.32K 0.06% 176
2025
Q2 		$145K Buy
5,477
+147
+3% +$3.87K 0.07% 161
2025
Q1 		$129K Buy
5,330
+3,124
+142% +$98.7K 0.07% 176
2024
Q4 		$88.8K Buy
2,206
+1,433
+185% +$81.7K 0.04% 195
2024
Q3 		$48.9K Buy
+773
New +$45.4K 0.02% 253

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

CNB Bank's VKTX Position: Q2 2026 in Review

CNB Bank reduced its Viking Therapeutics (VKTX) stake by 91% in Q2 2026, selling an estimated $91.1K and leaving 276 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

CNB Bank first reported a position in VKTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $151K in Q3 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • CNB Bank held 276 shares of Viking Therapeutics worth $10.8K as of Q2 2026.
  • CNB Bank sold 2,821 Viking Therapeutics shares in Q2 2026, an estimated $91.1K.
  • Viking Therapeutics made up ﹤0.01% of CNB Bank's portfolio in Q2 2026, its #419 holding.
  • CNB Bank first reported a position in Viking Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • CNB Bank's Viking Therapeutics position peaked at $151K in Q3 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on CNB Bank's 13F filing for Q2 2026, filed 6 Aug 2026.